- Home
- RVPH vs PULM Comparison
RVPH vs PULM Comparison
Compare RVPH & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVPH
- PULM
- Stock Information
- Founded
- RVPH 2006
- PULM 2003
- Country
- RVPH United States
- PULM United States
- Employees
- RVPH N/A
- PULM N/A
- Industry
- RVPH Biotechnology: Pharmaceutical Preparations
- PULM Biotechnology: Pharmaceutical Preparations
- Sector
- RVPH Health Care
- PULM Health Care
- Exchange
- RVPH Nasdaq
- PULM Nasdaq
- Market Cap
- RVPH 32.8M
- PULM 33.2M
- IPO Year
- RVPH N/A
- PULM N/A
- Fundamental
- Price
- RVPH $0.39
- PULM $6.21
- Analyst Decision
- RVPH Strong Buy
- PULM
- Analyst Count
- RVPH 5
- PULM 0
- Target Price
- RVPH $9.00
- PULM N/A
- AVG Volume (30 Days)
- RVPH 3.7M
- PULM 58.4K
- Earning Date
- RVPH 08-13-2025
- PULM 08-12-2025
- Dividend Yield
- RVPH N/A
- PULM N/A
- EPS Growth
- RVPH N/A
- PULM N/A
- EPS
- RVPH N/A
- PULM N/A
- Revenue
- RVPH N/A
- PULM $1,921,000.00
- Revenue This Year
- RVPH N/A
- PULM N/A
- Revenue Next Year
- RVPH N/A
- PULM $134.88
- P/E Ratio
- RVPH N/A
- PULM N/A
- Revenue Growth
- RVPH N/A
- PULM N/A
- 52 Week Low
- RVPH $0.30
- PULM $1.78
- 52 Week High
- RVPH $4.28
- PULM $10.40
- Technical
- Relative Strength Index (RSI)
- RVPH 35.22
- PULM 41.72
- Support Level
- RVPH $0.38
- PULM $6.28
- Resistance Level
- RVPH $0.45
- PULM $6.83
- Average True Range (ATR)
- RVPH 0.05
- PULM 0.44
- MACD
- RVPH 0.01
- PULM -0.05
- Stochastic Oscillator
- RVPH 17.57
- PULM 13.89
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).